Study Comparing Amivantamab and FOLFIRI with Cetuximab/Bevacizumab and FOLFIRI in Colorectal Cancer Patients Without KRAS/NRAS and BRAF Mutations

Inclusion Criteria

• Have a confirmed diagnosis of colon or rectal cancer that has come back, cannot be removed by surgery, or has spread to other parts of the body.
• The cancer must not have KRAS, NRAS, or BRAF mutations, as determined by local testing.
• Agree to provide a new or previous tumor sample after the most recent treatment, if possible.
• Have cancer that can be measured by scans or tests.
• Be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have received one previous treatment for metastatic colorectal cancer that included specific chemotherapy drugs, and the cancer must have shown signs of getting worse after this treatment.

Exclusion Criteria

• Have a history of certain lung diseases like interstitial lung disease, pneumonitis, or pulmonary fibrosis, or currently have these conditions.
• Have known allergies or intolerances to any of the study drugs or their components.
• Have another type of cancer that could interfere with the study.
• Have a specific genetic condition (mismatch repair deficiency or high microsatellite instability) and have not received immunotherapy.
• Have a tumor that is positive for HER2.
• Have previously been treated with irinotecan or drugs targeting EGFR or MET.